Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)

Author:

Mennitto Alessia1ORCID,Zattarin Emma1,Di Maio Massimo2,Bimbatti Davide3,De Giorgi Ugo4,Buti Sebastiano5ORCID,Santini Daniele6,Casadei Chiara4,Sorarù Mariella7,Messina Carlo8,Mucciarini Claudia9,Di Lorenzo Giuseppe1011,Roviello Giandomenico12,Buttigliero Consuelo13,Stellato Marco6,Sepe Pierangela1,Claps Melanie1ORCID,Guadalupi Valentina1ORCID,Ottini Arianna1,Pignata Sandro14,De Braud Filippo G.115ORCID,Verzoni Elena1ORCID,Procopio Giuseppe1ORCID

Affiliation:

1. Department of Medical Oncology, Fondazione Irccs Istituto Nazionale Dei Tumori, Milan, Italy

2. Department of Oncology, University of Turin, Ordine Mauriziano Hospital, Turin, Italy

3. Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto Iov Irccs, Padua, Italy

4. Department of Medical Oncology, Istituto Scientifico Romagnolo per Lo Studio E La Cura Dei Tumori (Irst), Irccs, Meldola, Italy

5. Medical Oncology Unit, University Hospital of Parma, Parma, Italy

6. Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy

7. Medical Oncology, Camposampiero Hospital, Camposampiero (Padua), Italy

8. Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy

9. Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy

10. Oncology Unit, Andrea Tortora Hospital, ASL Salerno, Pagani, Italy

11. Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy

12. Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy

13. Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy

14. Department of Urology and Gynecology, Istituto Nazionale Tumori Irccs Fondazione “G. Pascale”, Naples, Italy

15. Oncology and Hemato-Oncology Department, University of Milan, Milan, Italy

Funder

no funding to report

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3